Welcome to our dedicated page for Cosmos Holdings news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Holdings stock.
Cosmos Health Inc. reports developments across a vertically integrated healthcare platform that includes wholesale pharmaceutical distribution, contract manufacturing, proprietary nutraceutical brands and research and development. Recurring updates cover U.S. commercialization of the 18 Series nutraceutical portfolio, including Noor18, Liv18, Cur18 and Fort18, as well as Sky Premium Life orders, international distribution relationships and product launches.
Company news also covers financial results, margin and revenue drivers at Cana Laboratories, CosmoFarm and Decahedron, AI investments including the Cloudscreen drug-repurposing platform, and Nasdaq listing-compliance or governance matters tied to its common stock.
Cosmos Health (NASDAQ:COSM) projects Cur18™ will generate over $2.5 million in incremental annual U.S. revenue within 12–18 months based on its current commercialization strategy and internal assumptions. Cur18™ is a curcumin-based nutraceutical in the company’s 18 Series, planned initially for DTC e-commerce with potential retail expansion.
The projection depends on execution of pricing, sales volumes, and distribution expansion.
Cosmos Health (NASDAQ:COSM) launched the 18 Series in the U.S. on April 21, 2026: a science-first nutraceutical platform requiring a patented ingredient, peer-reviewed clinical evidence, and the exact clinical dose.
Three products—Noor18, Liv18, Cur18—target a combined $7.8B U.S. addressable market, cite published RCTs (7+ studies), and use patented actives to build a compounding portfolio aiming for 18 clinically validated products.
Cosmos Health (NASDAQ:COSM) completed Phase 1 for Liv18, finalizing product development, packaging, and initial commercial setup ahead of schedule. U.S. production begins April 2026 at GMP-certified, FDA-registered, UL-audited facilities to reduce tariff exposure and improve supply chain efficiency.
The company projects over $5M in annual revenue for Liv18 at approximately 75% gross margins, driven by a direct-to-consumer model and targeted advertising; early U.S. traction from other products informs commercial expectations.
Cosmos Health (NASDAQ:COSM) will launch Cur18 in the U.S. in Q2 2026, a patented, turmeric‑derived curcumin supplement standardized to ~50% curcuminoids and derived ~98.5% from turmeric.
Published pharmacokinetic research reports up to 39× higher free curcumin bioavailability and 49.5× higher AUC versus standard 95% extracts.
Cosmos Health (NASDAQ:COSM) announced expanded integration of artificial intelligence across operations on April 16, 2026, targeting efficiency, cost reduction, improved customer experience, and sales growth. In certain areas, AI may reduce specific operating expenses by up to 30%, depending on process and automation level.
The company is deploying AI across front-end order and customer management, back-end warehouse, inventory and supply chain, and its proprietary Cloudscreen platform for drug repurposing, supporting both operational gains and R&D efforts.
Cosmos Health (NASDAQ:COSM) reported record FY 2025 revenue of $65.27M, up 20% year-over-year, with gross profit of $7.90M (up 83%) and gross margin expanding 418 basis points to 12.10%. Cash rose to $3.46M and total assets to $65.48M; net loss was $19.14M.
The company highlighted contract manufacturing agreements for over 12 million units, 300,000+ Sky Premium Life purchase orders, a $300M financing facility for a digital asset treasury, and continued 2026 momentum across core segments.
Cosmos Health (NASDAQ:COSM) received a third consecutive purchase order from Pharmalink for 60,000 units of Sky Premium Life in the UAE, taking cumulative orders to 270,000 units since June 2024.
The order follows prior purchases of 130,000 and 80,000 units and advances Cosmos toward a 3 million‑unit five‑year partnership goal with Pharmalink.
Cosmos Health (NASDAQ:COSM) reported no material operational impact from the Iran and Middle East conflict and said record revenue momentum continues. Q3 2025 revenue reached $17.1M (+38% YoY); gross profit $2.6M (+116%) with a 15.21% margin; cash rose to $4.63M from $0.66M.
The company said U.S. rollout of NOOR collagen is on track, produced in GMP/FDA-registered facilities, and projected to exceed $12M revenue within 12 months with ~75% gross margins.
Cosmos Health (NASDAQ:COSM) will launch Liv18™ in the U.S. in Q2 2026, a 600 mg/day liver health supplement powered by patented BergacynFF®, supported by two randomized, double‑blind, placebo‑controlled trials showing 9–15% liver fat reduction versus placebo.
Products are manufactured in GMP, FDA‑registered U.S. facilities and target the $4.6B U.S. liver supplements market.
Cosmos Health (NASDAQ:COSM) announced that C-Scrub Wash 4%, made by subsidiary Cana Laboratories, successfully completed testing under EN 12791:2016+A1:2017, the European surgical hand disinfection standard. The independent QACS study confirmed effective antimicrobial activity for surgical hand antisepsis.
The company says this supports expansion into hospital, surgical, and institutional healthcare channels, strengthens the C-Scrub brand, and complements growing commercial availability in the United Kingdom.